Why the study?
Cancer survivors face increased risks of premature cardiovascular disease from cardiotoxic therapies, suggesting heightened vulnerability to cardiovascular complications from COVID-19.
Are cancer survivors more vulnerable to cardiovascular complications from COVID-19?
Are cancer survivors more vulnerable to cardiovascular complications from COVID-19?
Cancer survivors may require special cardiovascular care when infected with COVID-19 due to increased vulnerability to cardiovascular complications from prior cardiotoxic treatments and shared risk factors.
Answers are grounded in this paper and cite their sources.
Raises concern for excess CV risk in cancer survivors with COVID-19; hypothesis-generating and requires prospective validation before guiding practice.
Coronavirus disease 2019 (COVID-19) has been declared a global pandemic by the World Health Organization on March 11, 2020. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2). Although primarily a respiratory disease, cardiovascular complications of COVID-19 have been increasingly recognized. In addition, higher fatality has been reported in COVID-19 patients with underlying cardiovascular diseases. Cancer survivors have a considerably increased risk for premature cardiovascular diseases, mainly due to cardiotoxic cancer treatments. Therefore, it is foreseeable that cancer survivors will be more vulnerable to cardiovascular complications caused by COVID-19. In this review, three scenarios for increased cardiovascular complications of COVID-19 in cancer patients are proposed. In the first scenario, cardiotoxic cancer treatment and COVID-19 synergize to exacerbate direct myocardial damage. In the second scenario, cardiotoxic cancer treatment leads to a reduced cardiac reserve in cancer survivors, making them more vulnerable to COVID-19 in a “two-hit” model. The third scenario suggests that several shared risk factors may aggravate cardiovascular complications caused by both cancer treatment and COVID-19. Taken together, cancer survivors may be more vulnerable to cardiovascular complications when challenged by the COVID-19, and special cardiovascular care should be given to these patients.
No takes yet. Share an insight, caveat, or question.
Beshay N. Zordoky (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: